Group 1 - The company will hold its shareholder meeting on September 17, 2025, at 14:00 in Beijing [1][4] - Voting will be conducted through a combination of on-site and online methods, with specific time slots for each [1][2] - The online voting system will be managed by the Shanghai Stock Exchange, with voting available from 9:15 to 15:00 on the day of the meeting [1][4] Group 2 - Shareholders registered by the close of trading on September 9, 2025, are eligible to attend the meeting [6] - The meeting will not provide gifts, and attendees will bear their own travel and accommodation costs [6] - The company has specified that no related shareholders need to abstain from voting [2]

Core Viewpoint - In the first half of 2025, JianKai Technology Co., Ltd. reported a slight increase in revenue but a significant decline in net profit, indicating challenges in domestic sales while experiencing growth in international orders [1][2]. Financial Performance - The company achieved operating revenue of 130 million yuan, a year-on-year increase of 0.89% [1]. - Product sales revenue was 126 million yuan, a decrease of 0.26% year-on-year, while technical service revenue reached 3.78 million yuan, an increase of 83.77% [1]. - Domestic sales revenue fell to 20.48 million yuan, down 58.35% year-on-year, primarily due to a major domestic client reducing orders [1]. - International sales revenue increased to 105 million yuan, a growth of 36.96% year-on-year, driven by a rise in orders from overseas pharmaceutical clients [1]. - The net profit attributable to shareholders was 22.05 million yuan, a decline of 21.08% year-on-year, and the net cash flow from operating activities decreased by 88.22% [1]. Research and Development - Total R&D investment amounted to 42.60 million yuan, an increase of 52.44% year-on-year, with R&D expenses accounting for 32.84% of operating revenue, up 11.11 percentage points [2]. - The increase in R&D investment is attributed to the ongoing Phase III clinical trial for the PEG-Irinotecan project for small cell lung cancer, which began patient enrollment in September 2024 [2]. Operational Strategy - Despite a challenging global political and economic landscape and intensified competition in the domestic pharmaceutical raw materials sector, the company maintained a stable operational development [2]. - The company leveraged its unique advantages in PEG modification technology across multiple fields and optimized its production quality management system [2]. - JianKai Technology successfully accumulated a substantial reserve of overseas pharmaceutical orders, laying a solid foundation for future business development [2].

Group 1 - The company announced the resignation of independent director Wang Chunfei due to the completion of his six-year term, which will result in the independent director count falling below one-third of the total board members [3][4][5] - The board has proposed Lin Wen as a candidate for the independent director position, pending approval from the shareholders' meeting [4][5][6] - If elected, Lin Wen will also take on roles in the compensation and assessment committee, audit committee, and nomination committee [6][7] Group 2 - The company held its 13th meeting of the third board on August 27, 2025, where several key resolutions were passed, including the approval of the 2025 semi-annual report [14][15][16] - The board also approved the proposal to cancel the supervisory board and amend the company's articles of association to enhance governance structure [19][21][22] - The company plans to hold a temporary shareholders' meeting on September 17, 2025, to discuss the resolutions passed by the board [57][58][59] Group 3 - The company reported a provision for asset impairment of 4.2167 million yuan for the first half of 2025, which includes 3.5847 million yuan for asset impairment losses and 632,000 yuan for credit impairment losses [38][40][41] - The board's audit committee and supervisory board have both agreed that the provision for asset impairment is in line with accounting standards and reflects the company's financial status accurately [43][45]

Core Viewpoint - The announcement from JianKai Technology regarding the approval of the 2025 semi-annual report and its summary by the third board meeting indicates the company's ongoing commitment to transparency and governance [2] Group 1 - JianKai Technology's third board meeting approved multiple proposals, including the 2025 semi-annual report and its summary [2]

Group 1 - The company, JianKai Technology, announced the approval of multiple proposals during the 12th meeting of its third supervisory board, including the 2025 semi-annual report and its summary [2]

Group 1 - The company announced the nomination of Ms. Lin Wen as an independent director candidate for its third board of directors [1]

北京键凯科技股份有限公司 投资者关系管理制度 第一章 总则 第一条 为促进北京键凯科技股份有限公司（以下简称"公司"）治理结构 的改善，增强信息披露的效能，加强公司与投资者和潜在投资者（以下统称"投 资者"）之间的信息沟通，形成公司与投资者的良性互动，倡导理性投资，并在 投资公众中建立公司的诚信度，根据《中华人民共和国公司法》《中华人民共和 国证券法》《上海证券交易所科创板股票上市规则》《上市公司投资者关系管理工 作指引》等相关法律法规、规范性文件的规定和《北京键凯科技股份有限公司章 程》（以下简称"公司章程"）并结合公司的实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回 报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理的目的是： (一) 促进公司与投资者之间的良性关系，增进投资者对公司的进一步了解 和熟悉； 1 见建议，及时回应投资者诉求。 （四）诚实守信原则。公司在投资者关系管理活动中应当注重诚信、坚守底 线、 ...

北京键凯科技股份有限公司 募集资金专项存储及使用管理制度 第一章 总则 第一条 为规范北京键凯科技股份有限公司（以下简称"公司"）募集资金的 管理和使用，最大限度地保障投资者的利益，根据《公司法》《证券法》《首次 公开发行股票注册管理办法》《上市公司证券发行注册管理办法》《上市公司募 集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》等有关法律、法规和规定的要 求，结合公司的实际情况，特制定本制度。 第二条 本制度所称募集资金是指公司通过向不特定对象发行证券（包括首 次公开发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公 司债券等）以及向特定对象发行证券向投资者募集的资金，但不包括公司实施股 权激励计划募集的资金。 第三条 公司的董事、高级管理人员应当勤勉尽责，督促公司规范使用募集 资金，自觉维护公司募集资金安全，不得参与、协助或纵容公司擅自或变相改变 募集资金用途。 第四条 公司控股股东、实际控制人不得直接或者间接占用或者挪用公司募 集资金，不得利用公司募集资金及募集资金投资项目（以下简称"募投项目"）获 取不正当利益。 ...

北京键凯科技股份有限公司 委托理财管理制度 第一章 总 则 第一条 为规范北京键凯科技股份有限公司（以下简称"公司"）的理财交 易行为，保证公司资金、财产安全，有效防范投资风险，维护股东和公司的合法 权益，根据《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司 自律监管指引第 5 号——交易与关联交易》等法律、法规及《北京键凯科技股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，结合公司实际情况， 特制定本制度。 第二条 本制度所称"委托理财"是指在国家政策允许及有效控制投资风险 的情况下，公司（含全资子公司及控股子公司）在控制投资风险的前提下，以提 高资金使用效率、增加现金资产收益为原则，委托银行、信托、证券、基金、期 货、保险资产管理机构、金融资产投资公司、私募基金管理人等专业理财机构对 公司财产进行投资和管理或者购买相关理财产品的行为。。 第三条 本制度适用于公司本部及各所属企业。各企业应根据国家有关法律 法规及本制度的相关规定，结合企业自身货币资金内部控制及管理的需要，建立 更具体、更贴近各企业自身需求的货币资金内部控制制度，并组织实施。 第二章 管理原则 第四条 本制度适用于公司 ...

第三条 公司依照国家有关法律、法规、规章及本制度的规定，结合公司所 处行业和生产经营特点，建立健全内部审计制度，防范和控制公司风险，增强公 司信息披露的可靠性。 第四条 公司董事会对内部控制制度的建立健全和有效实施负责，重要的内 部控制制度应当经董事会审议通过。公司董事会及其全体成员应当保证内部控制 相关信息披露内容的真实、准确、完整。 第二章 内部审计机构和人员 北京键凯科技股份有限公司 内部审计管理制度 第一章 总则 第一条 为了加强公司内部审计工作，降低决策风险，提高企业经济效益， 保障企业经营活动健康发展，根据《中华人民共和国审计法》《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》《审计署关于内部审计工作 的规定》及《公司章程》等相关法律法规、规范性法律文件，结合公司的实际情 况，制定本制度。 第二条 本制度所称内部审计，是指公司内部设立的内审部，依据国家有关 法律法规、财务会计制度和公司内部管理规定，对其内部控制和风险管理的有效 性、财务信息的真实性和完整性以及经营活动的效率和效果等开展的一种评价活 动。 第五条 公司在董事会下设立审计委员会，制定审计委员会工作细则。 第六条 公 ...